The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback